EUTECNIQAtlas

Every page of EUTECNIQ on one mapArrow keys move through results · Enter opens · Esc closes

Supplements A–Z · by effect 87 graded findings

Digestion and gut

What human research has studied for iBS, constipation, nausea and gut symptoms, across every ingredient in this guide, strongest evidence first. A grade describes the evidence, not a recommendation.

Education, not medical advice. These statements have not been evaluated by the Food and Drug Administration. This information is not intended to diagnose, treat, cure or prevent any disease, or to replace any medication or medical advice. Ask a doctor or pharmacist before use, especially with medicines, in pregnancy or for a child.

Summary

How strong the evidence is

Show

Where digestion and gut sits on the supplement body map; colored by its strongest grade here.

Findings

Findings by ingredient

Digestion and gut: findings by ingredient and grade
IngredientGradeWhat was studied and found
Saccharomyces boulardiiAAntibiotic-associated diarrhea in children and adults. A 2015 meta-analysis of 21 RCTs (4,780 participants) found S. boulardii lowered antibiotic-associated diarrhea risk from 18.7% to 8.5% versus placebo or no treatment (children 20.9% to 8.8%; adults 17.4% to 8.2%). sources
Bacillus coagulans (Heyndrickxia coagulans)BIrritable bowel syndrome in adults (strain Unique IS2). In an RCT of 136 adults with IBS, Unique IS2 (2 billion CFU/day for 8 weeks) improved abdominal pain/discomfort and complete spontaneous bowel movements versus placebo. sources
Bacillus coagulans (Heyndrickxia coagulans)BIrritable bowel syndrome in children aged 4–12 (strain Unique IS2). In a double-blind RCT of 141 children, 8 weeks of Unique IS2 chewable tablets reduced pain intensity and improved stool consistency, bloating and other IBS symptoms versus placebo. sources
Bifidobacterium animalis subsp. lactis BB-12BInfant colic in breastfed infants (larger trial). In an RCT of 192 breastfed infants with colic in China, BB-12 (1 x 10^9 CFU/day for 21 days) increased the share with at least 50% less crying and fussing versus placebo. sources
Bifidobacterium animalis subsp. lactis BB-12BInfant colic in breastfed infants (smaller trial). In an RCT of 80 exclusively breastfed infants with colic in Italy, BB-12 (1 x 10^9 CFU/day for 28 days) increased the rate of at least 50% less daily crying versus placebo. sources
Escherichia coli Nissle 1917 (EcN)BUlcerative colitis: relapse and remission versus mesalazine (pooled trials). A 2015 meta-analysis of 6 trials (719 patients) found relapse rates similar with EcN and mesalazine (36.8% vs 36.1%); remission induction was similar to controls, and only one study used a placebo comparison. sources
Escherichia coli Nissle 1917 (EcN)BAcute diarrhea in infants and toddlers. In a double-blind RCT of 113 children aged 2–47 months, EcN suspension shortened the median time to treatment response (2.5 vs 4.8 days) versus placebo. sources
Escherichia coli Nissle 1917 (EcN)BDiarrhea lasting more than 4 days in infants and toddlers. In an RCT of 151 children aged 1–47 months, 21 days of EcN raised response rates versus placebo (day 21: 98.7% vs 71.1%). sources
Galactooligosaccharides (GOS)BLactose intolerance symptoms. In a 30-day double-blind RCT in 377 patients with lactose intolerance, 40% given the purified GOS RP-G28 had a 4-point or greater symptom-score reduction or no symptoms, versus 26% on placebo (P = 0.016). sources
GingerBNausea and vomiting of pregnancy. NCCIH states research shows ginger may be helpful; most studies tested dietary supplements rather than foods. sources
Inulin and FOSBBowel movement frequency. A 2019 meta-analysis of 47 publications found short-chain β-fructans (DP below 10) increased stool frequency by 0.36 bowel movements per day; long-chain β-fructans (DP 10 or more) had no significant effect. sources
Lacticaseibacillus rhamnosus GG (LGG)BAntibiotic-associated diarrhea. A 2015 meta-analysis of 12 RCTs (1,499 participants) found LGG lowered risk from 22.4% to 12.3% (11 RCTs; low-quality evidence); the reduction was significant in children (5 RCTs) but not in adults overall (6 RCTs). sources
Lacticaseibacillus rhamnosus GG (LGG)BDuration of diarrhea in children with acute gastroenteritis (pooled trials). A 2019 meta-analysis of 18 RCTs (4,208 children) found LGG shortened diarrhea by 0.85 day and hospital stays, with no effect on stool volume; heterogeneity was high and trials had methodological limitations. sources
Lacticaseibacillus rhamnosus GG (LGG)BAbdominal pain-related functional GI disorders in children. A 2011 meta-analysis (3 RCTs, 290 children) found more treatment responders with LGG than placebo (RR 1.31), especially in irritable bowel syndrome; no difference in functional abdominal pain or dyspepsia. sources
Lactiplantibacillus plantarum 299vBIrritable bowel syndrome symptoms in adults (pooled single-strain trials). A 2026 meta-analysis of 6 placebo-controlled RCTs of 299v alone found lower abdominal pain severity and more patients reporting symptom improvement, but no significant effect on bloating or constipation resolution; heterogeneity varied. sources
Lactiplantibacillus plantarum 299vBIrritable bowel syndrome global symptoms (broad meta-analysis). A 2023 meta-analysis of 82 IBS trials (10,332 patients) rated the certainty of evidence for a benefit of L. plantarum 299V on global symptoms as low. sources
Lactiplantibacillus plantarum 299vBIrritable bowel syndrome (largest single trial). In a double-blind RCT of 214 patients meeting Rome III criteria, 4 weeks of 299v lowered abdominal pain severity and frequency and bloating versus placebo. sources
Limosilactobacillus reuteri DSM 17938BCrying and fussing in infants with colic (pooled individual data). A 2018 individual-participant meta-analysis of 4 double-blind RCTs (345 infants) found 25.4 fewer minutes of crying/fussing at day 21 versus placebo; effects were large in breastfed infants but not significant in formula-fed infants. sources
Limosilactobacillus reuteri DSM 17938BAcute gastroenteritis in children. A 2019 meta-analysis of 4 RCTs (347 children) found diarrhea shortened by 0.87 day versus placebo or no treatment; the authors note small effect sizes of limited clinical relevance and trial limitations. sources
Peppermint oilBIrritable bowel syndrome (IBS) symptoms. A 2022 review of 10 studies (1,030 participants) found enteric-coated peppermint oil better than placebo for overall IBS symptoms, with more, mostly mild, side effects; a 2021 ACG guideline recommended it. sources
ProbioticsBAntibiotic-associated diarrhea. A 2015 meta-analysis of 21 trials (4,780 participants) found S. boulardii lowered antibiotic-associated diarrhea from 18.7% to 8.5% versus placebo or no treatment (RR 0.47, 95% CI 0.38 to 0.57); in adults, from 17.4% to 8.2%. sources
ProbioticsBC. difficile diarrhea during antibiotic use. A 2017 analysis of 31 studies (8,672 patients, mostly hospitalized) concluded with moderate certainty that probiotics can reduce risk; the best types, doses and durations are uncertain. sources
ProbioticsBNecrotizing enterocolitis in preterm infants. An AGA 2020 review (63 trials, 15,712 infants) found specific Lactobacillus/Bifidobacterium combinations reduced severe disease and mortality, but a 2023 Cochrane review called evidence for infants under 32 weeks or 1,500 g inconclusive. sources
Resistant starchBBowel function in healthy adults. A 2017 meta-analysis of RCTs in healthy adults found resistant starch increased fecal wet weight (35.51 g/day) and butyrate and lowered fecal pH, but did not significantly change defecation frequency. sources
Saccharomyces boulardiiBAcute gastroenteritis in children. A 2020 meta-analysis of 29 RCTs found S. boulardii shortened diarrhea by 1.06 days (23 RCTs, 3,450 children) versus placebo or no treatment, but evidence quality was very low and heterogeneity high. sources
Saccharomyces boulardiiBHelicobacter pylori eradication therapy (added to standard antibiotics). A 2015 meta-analysis of 11 RCTs (2,200 participants) found adding S. boulardii raised eradication from 71% to 80% and reduced therapy-related side effects, particularly diarrhea and nausea. sources
Sangre de gradoBAcute travelers' diarrhea (latex-derived SP-303). In an RCT of 184 travelers, SP-303 125-500 mg four times daily for 2 days shortened time to the last unformed stool (30.3-32.6 h vs 38.7 h with placebo). sources
Sangre de gradoBNon-infectious diarrhea in adults with HIV (crofelemer, prescription drug). In the phase 3 ADVENT trial (376 patients), more patients responded to crofelemer 125 mg twice daily than to placebo over 4 weeks (17.6% vs 8.0%). sources
Vitamin B6BNausea and vomiting in pregnancy. Two RCTs found 30–75 mg/day oral pyridoxine significantly decreased nausea, but a Cochrane review could not draw firm conclusions on vitamin B6's value. sources
ZincBAcute diarrhea in children. A 2016 Cochrane review (33 trials, 10,841 children) found diarrhea about half a day shorter in children over 6 months, with no effect in infants under 6 months (low certainty). sources
AndrographisCUlcerative colitis. In one trial, higher-dose extract produced more clinical responses than placebo; another found it comparable to mesalamine. MSK says additional studies are needed to confirm these effects. sources
AsafoetidaCFunctional dyspepsia (Cochrane assessment). A 2023 Cochrane review found one placebo-controlled trial (43 participants): asafoetida may improve dyspepsia symptoms (SMD −1.51), with low-certainty evidence. sources
AsafoetidaCFunctional dyspepsia symptoms in adults. A double-blind RCT in 62 participants with functional dyspepsia symptoms (250 mg/day of a hydrogel formulation for 14 days) reported less bloating, early satiety and heartburn than placebo. sources
Bacillus coagulans (Heyndrickxia coagulans)CStool frequency in adults with chronic constipation (strain Unique IS2). A 2022 meta-analysis of constipation RCTs found probiotics overall increased stool frequency, but the Bacillus coagulans Unique IS2 subgroup did not show a significant effect. sources
Bacillus coagulans (Heyndrickxia coagulans)CFunctional gastrointestinal complaints in healthy adults (strain GBI-30, 6086). In a double-blind RCT of 111 adults in China, GBI-30, 6086 (1 x 10^9/day for 4 weeks) increased stools per week and improved fecal consistency versus placebo, with fewer participants constipated. sources
Bacillus coagulans (Heyndrickxia coagulans)CFunctional gas and bloating (strain MTCC 5856). In a double-blind RCT of 70 adults in India, MTCC 5856 (2 billion spores/day for 4 weeks) lowered indigestion (gas and bloating) scores versus placebo. sources
Bifidobacterium animalis subsp. lactis BB-12CDefecation frequency in adults with low stool frequency and abdominal discomfort. In one RCT of 1,248 adults, 4 weeks of BB-12 (1 or 10 billion CFU/day) raised average defecation frequency versus placebo; the main responder analysis (OR 1.31, P = 0.071) and global relief of abdominal discomfort were not significant. sources
BilberryCMild diarrhea (EU traditional use, dried fruit). The EU monograph accepts dried bilberry fruit tea for mild diarrhea and mouth rinses for minor oral inflammation exclusively on the basis of long-standing use. sources
BoswelliaCCrohn's disease and collagenous colitis. No significant benefit was found for maintaining remission in Crohn's disease; evidence in collagenous colitis is unclear or negative. sources
BPC-157CUlcerative colitis (rectal enema). One randomized placebo-controlled study (53 patients; 80 mg enema daily for 2 weeks), reported only as a meeting abstract, found no clear between-group difference; FDA found a lack of evidence to support effectiveness. sources
Carrageenan and agarCRelapse of ulcerative colitis with carrageenan. RCT of 12 people with ulcerative colitis in remission on a no-carrageenan diet: 3 given carrageenan capsules relapsed versus none given placebo, within up to one year. sources
Carrageenan and agarCInflammation and gut symptoms in ulcerative colitis. Crossover pilot RCT in 7 people with quiescent ulcerative colitis: 7 days of food-grade carrageenan did not change disease activity or inflammatory markers versus placebo. sources
ChamomileCInfant colic and childhood diarrhea. Combination products containing chamomile may help; chamomile alone has not been shown to help. sources
Escherichia coli Nissle 1917 (EcN)CIrritable bowel syndrome. A 2026 meta-analysis of 2 placebo-controlled RCTs of EcN alone found no significant difference from placebo in reduction of abdominal pain or urgency. sources
FennelCInfant colic. One RCT in 125 infants aged 2–12 weeks found fennel seed oil emulsion relieved colic in 65% versus 23.7% with placebo; no side effects were reported. sources
Galactooligosaccharides (GOS)CSymptoms of irritable bowel syndrome (IBS). In a 12-week randomized controlled trial in 44 patients with IBS, 3.5 g/day trans-galactooligosaccharide improved stool consistency, flatulence, bloating and global assessment, and 7 g/day improved global assessment and anxiety scores; placebo had no effect. sources
Galactooligosaccharides (GOS)CFunctional constipation. In a 4-week double-blind RCT in 63 patients meeting Rome IV criteria (34 GOS, 29 placebo), GOS improved daily bowel movements and stool shape versus placebo. sources
Gentian rootCDyspeptic symptoms in adults. The main gentian-only study was open and uncontrolled: 205 patients took a gentian dry extract for 15 days, with 68% average symptom improvement. EMA said the open design only supports plausibility. sources
Gentian rootCSaliva and gastric secretion (bitter-taste response). In a Latin-square study in 24 healthy volunteers, 2% gentian tincture increased salivary secretion over 30 minutes, similar to a citric acid control; older small studies reported increased saliva and gastric secretion. sources
Gentian rootCLoss of appetite and mild digestive disorders (EU traditional use). The EU monograph accepts these uses exclusively on the basis of long-standing use, not proof of efficacy from clinical trials. sources
GingerCMotion sickness. NCCIH states most studies of ginger for motion sickness haven't shown it to be helpful. sources
GingerCChemotherapy-related and postoperative nausea. Uncertain whether ginger adds benefit to standard treatment for chemotherapy nausea, or helps nausea after surgery. sources
GlucomannanCFunctional constipation in children. A meta-analysis of 3 RCTs (122 children) found more frequent bowel movements but no difference in stool consistency or treatment success; the authors urge caution given the small samples. sources
Inulin and FOSCSymptoms of irritable bowel syndrome (IBS). A 2019 meta-analysis of 11 RCTs (729 adults with IBS or other functional bowel disorders) found prebiotics did not improve symptoms or quality of life; inulin-type fructans worsened flatulence. No included study was at low risk of bias in every category. sources
Java turmericCDigestive complaints (fullness, slow digestion, flatulence). EMA found insufficient clinical-trial evidence; EU use rests on long-standing traditional use. A 12-person study of curcumin (20-80 mg) showed gallbladder contraction, which EMA judged insufficient for firm conclusions. sources
JujubeCChronic idiopathic constipation. A 12-week placebo-controlled trial in 37 patients with prolonged transit time reported shorter transit time and milder symptoms with a liquid jujube extract; 16 of 19 placebo patients dropped out because of severe constipation. sources
JujubeCFunctional constipation in children. A double-blind trial in children aged 2-10 (62 completed 3 months) found better response scores, fewer soiling episodes and less pain with jujube syrup than with polyethylene glycol. sources
Lacticaseibacillus paracasei strain Shirota (LcS)CStool frequency and consistency in adults with functional constipation. In a 2014 meta-analysis, L. casei Shirota did not significantly change stool frequency (-0.2 bowel movements/week) or stool consistency, unlike B. lactis; attrition and reporting bias were high across trials. sources
Lacticaseibacillus paracasei strain Shirota (LcS)CIrritable bowel syndrome. A 2026 meta-analysis of 2 placebo-controlled RCTs found no significant effect of L. casei Shirota on abdominal pain, bloating, flatulence or overall IBS symptoms. sources
Lacticaseibacillus paracasei strain Shirota (LcS)CAntibiotic-associated diarrhea in hospitalized patients with spinal cord injury. In an RCT of 164 patients (control: no probiotic), daily LcS during antibiotics and for 7 days after was associated with less antibiotic-associated diarrhea (17.1% vs 54.9%); authors called for a placebo-controlled trial. sources
Licorice rootCDigestive symptoms. NCCIH describes the evidence for digestive symptoms as unclear. sources
Limosilactobacillus reuteri DSM 17938CPreterm infants: necrotizing enterocolitis, late-onset sepsis and feeding. A 2023 meta-analysis of 12 RCTs (2,284 preterm infants) found less necrotizing enterocolitis (RR 0.57; 8 RCTs), less late-onset sepsis and faster full feeds, but no mortality difference; certainty was very low. sources
Limosilactobacillus reuteri DSM 17938CAntibiotic-associated diarrhea in children. A 2026 systematic review of 3 RCTs (998 children analyzed) found lower risk with use for up to 21 days (2 RCTs; RR 0.50) but no effect with use of 14 days or less or with follow-up to 56 days. sources
Mastic gumCFunctional dyspepsia in adults. A double-blind RCT in 148 patients (350 mg three times daily for 3 weeks) found lower dyspepsia symptom scores than placebo; marked improvement occurred in 77% versus 40%. sources
Mastic gumCFunctional dyspepsia (Cochrane assessment). A 2023 Cochrane review rated this single trial (148 participants; SMD −0.33 versus placebo) as low-certainty evidence that mastic may improve dyspepsia symptoms. sources
Mastic gumCFunctional dyspepsia (crossover trial). A randomized three-way crossover trial (4-week phases) reported fewer symptoms with mastiha capsules (1.4 g/day) or mastiha-water than in a no-intervention period; there was no placebo. sources
Mastic gumCHelicobacter pylori infection. In a pilot RCT of 52 infected patients, mastic gum alone for 14 days cleared infection in 4/13 and 5/13; standard triple therapy cleared 10/13. sources
Mastic gumCInflammatory bowel disease. A 2023 systematic review found eight human and animal studies (seven from Greece; clinical doses 2.2–2.8 g/day) and concluded that more high-quality clinical trials are needed for reliable conclusions. sources
NeemCStomach acid secretion. A small study found neem bark extract reduced stomach acid secretion; MSK states more human studies are needed. sources
NoniCEarly postoperative nausea. MSK cites a small clinical study suggesting noni may reduce early postoperative nausea; further research is needed to confirm the effect. sources
Peppermint oilCIndigestion. Peppermint oil combined with caraway oil may relieve indigestion; peppermint oil alone has no such evidence and may worsen indigestion in some people. sources
Peppermint oilCChemotherapy-related nausea and vomiting. NCCIH reports that inhaled peppermint oil or oral peppermint may reduce chemotherapy-related nausea and vomiting. sources
PerillaCLeaf extract: gastrointestinal discomfort. In a 4-week pilot RCT of 50 adults, symptoms improved within the perilla group; versus placebo, only a combined bloating and discomfort score in women differed significantly. sources
Prickly pearCIrritable bowel syndrome symptoms (nopal fiber). A one-week RCT in 60 people with IBS found more reported adequate relief with 20 g/day (87%) and 30 g/day (80%) nopal fiber than placebo (33%); 30 g/day caused more loose stools. sources
ProbioticsCIrritable bowel syndrome symptoms. A 2018 review of 53 studies (5,545 participants) found possible benefits on global symptoms and pain, but no definite conclusions or identification of which strains help. sources
PurslaneCFunctional constipation. An 8-week double-blind RCT in 60 patients found an ethanol extract of the aerial parts improved complete spontaneous bowel movements, symptoms and quality of life versus placebo. sources
Saccharomyces boulardiiCClostridium difficile-associated diarrhea. In the 2015 meta-analysis of 21 RCTs, the reduction was significant in children (2 RCTs, 579 participants) but not in adults (9 RCTs, 1,441 participants; RR 0.8, 95% CI 0.47–1.34). sources
SennaCChronic idiopathic constipation in adults. In one 28-day double-blind trial (90 patients across senna, magnesium oxide and placebo arms), overall improvement was 69.2% with senna 1.0 g versus 11.7% with placebo; bowel movements and quality of life improved. No severe adverse events. sources
SennaCChronic constipation in adults (pooled trials). A 2023 meta-analysis pooling two senna trials found 61% responded versus 28% on control, a difference that was not statistically significant (RR 2.78, 95% CI 0.93–8.27). sources
SennaCConstipation in palliative care. A Cochrane review of five small trials comparing laxatives, including senna, found similar effectiveness, with evidence too limited to rank them. sources
SpearmintCHeartburn and lower esophageal sphincter pressure. In a randomized crossover study in healthy volunteers, spearmint (0.5 or 500 mg) did not change sphincter pressure or reflux; the high dose increased symptom scores. sources
BPC-157DGastrointestinal and liver injury models (animal studies). In rats, BPC-157-related substances reduced colonic fistulas, liver lesions and gastrointestinal lesions induced by various challenges; FDA notes dose-response, molecular targets and mechanism of action remain unestablished. sources
Escherichia coli Nissle 1917 (EcN)XActive ulcerative colitis, EcN added to conventional therapy. In a double-blind RCT of 100 patients, EcN add-on without prior ciprofloxacin gave fewer remissions than placebo (54% vs 89%, per protocol) and the most withdrawals. sources
Lacticaseibacillus rhamnosus GG (LGG)XAcute gastroenteritis in US preschool children (large RCT). In a double-blind trial of 971 children aged 3 months to 4 years in 10 US emergency departments, a 5-day LGG course (1 x 10^10 CFU twice daily) did not improve outcomes versus placebo. sources
Limosilactobacillus reuteri DSM 17938XInfant colic in a community sample of breastfed and formula-fed infants. In a double-blind RCT of 167 infants in Melbourne, DSM 17938 (1 x 10^8 CFU/day for one month) did not reduce crying; the probiotic group cried or fussed 49 minutes more at 1 month. sources
Limosilactobacillus reuteri DSM 17938XFunctional abdominal pain and functional constipation in children. A 2026 meta-analysis of single-strain RCTs found no significant benefit on responder rates in functional abdominal pain (5 RCTs, 302 children) or on stool frequency in functional constipation (5 RCTs, 276 children). sources
ProbioticsXAcute infectious diarrhea in children. A 2020 Cochrane review (82 RCTs) reported shorter illness, but low-bias studies showed no difference, and two large emergency-department trials, one of LGG and one of an L. rhamnosus R0011 plus L. helveticus R0052 combination, found the probiotics no better than placebo. sources
A
Consistent results from several randomized trials or a systematic review of them
B
Some positive randomized trials, but small, short, few or inconsistent
C
Limited human evidence: single small trials, observational data or mixed results
D
Laboratory or animal evidence only; not shown in people
X
Well-designed human trials found no meaningful effect

All effect categories · All entries A–Z · Interactions

Health information notice

These statements have not been evaluated by the Food and Drug Administration. Nothing on this site is intended to diagnose, treat, cure or prevent any disease. The information is for general education only. It is not medical advice and does not replace advice, diagnosis or treatment from a qualified health professional, or any medication a clinician has prescribed.

Do not start, stop or change any medicine, supplement or herbal product because of something you read here. Talk to your doctor or pharmacist first, especially if you are pregnant or breastfeeding, have a medical condition, take any medicines, are preparing for surgery, or are caring for a child. Research findings, traditional uses and safety data are reported as their sources state them; they are not recommendations or claims about any product. If you think you may have a medical emergency, call your doctor or 911 at once.

EUTECNIQ Sciences sells no supplements or health products today and receives nothing from any product or ingredient mentioned on this site; any commercial interest it later has in an ingredient will be stated on that ingredient’s page.

Ready to check what you take?

Free tools built on published reference values, each with its sources and its limits. Your lists stay in your browser.